Oligonucleotide · developed by Sarepta Therapeutics
SRP-1003 is an agent given by subcutaneous injection and studied in myotonic dystrophy type 1.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06138743 | Phase 1/2 | Myotonic Dystrophy 1 | Enrolling by invitation | SRPT |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Myotonic Dystrophy 1
Updated Nov 1, 2026. Something wrong or missing? Report it on the SRPT page.
See SRPT's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
SRPT catalysts and pipeline →